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OBJECTIVE — Continuously administered insulin is limited by the need for frequent blood
glucose measurements, dose adjustments, and risk of hypoglycemia. Regimens based on gluca-
gon-like peptide 1 (GLP-1) could represent a less complicated treatment alternative. This alter-
native might be advantageous in hyperglycemic patients hospitalized for acute critical illnesses,
who beneﬁt from near normoglycemic control.
RESEARCH DESIGN AND METHODS — In a prospective open randomized crossover
trial, we investigated eight clinically stable type 2 diabetic patients during intravenous insulin or
GLP-1 regimens to normalize blood glucose after a standardized breakfast.
RESULTS — The time to reach a plasma glucose below 115 mg/dl was signiﬁcantly shorter
during GLP-1 administration (252  51 vs. 321  43 min, P  0.01). Maximum glycemia
(312  51 vs. 254  48 mg/dl, P  0.01) and glycemia after 2 h (271  51 vs. 168  48 mg/dl,
P  0.012) and after 4 h (155  51 vs. 116  27 mg/dl, P  0.02) were signiﬁcantly lower
during GLP-1 administration.
CONCLUSIONS — GLP-1 infusion is superior to an established insulin infusion regimen
with regard to effectiveness and practicability.
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A
dmission hyperglycemia is associ-
ated with an increased morbidity
and mortality in diabetic and non-
diabetic patients hospitalized for acute
criticalconditions(1,2).Severalinterven-
tion studies of patients with acute myo-
cardial infraction or cardiac surgery that
used intravenously administered regular
humaninsulinsuggestthatnormalization
of hyperglycemia reduces morbidity as
well as mortality in these patients (3–6).
Insulin-basedregimens,however,require
frequent blood glucose measurements
and adjustments of infusion rate to
achieve this goal. In addition, hypoglyce-
miaisafrequentandimportantsideeffect
thathasbeenshowntobeassociatedwith
a worse outcome in patients hospitalized
with acute coronary syndromes (7). Hy-
poglycemiawasalsodiscussedasareason
for the worse outcome in the intensive
group in the recent National Investigators
CollaborationonEnoxaparin(NICE)trial
(8).
Glucagon-like peptide 1 (GLP-1) is
an insulinotropic glucagonostatic gastro-
intestinal hormone that lowers glucose at
ﬁxed rates of administration in a glyce-
mia-dependent manner and, therefore,
doesnotcausehypoglycemia(9).Theaim
of our study was to compare for the ﬁrst
time the efﬁcacy and safety of intrave-
nously administered GLP-1 with an es-
tablished intravenous insulin regimen in
clinically stable hyperglycemic type 2 di-
abetic patients as a pilot trial for possible
future investigations in patient popula-
tions with acute, critical conditions.
RESEARCH DESIGN AND
METHODS— We performed a pro-
spectiveopenrandomizedcross-overtrial
ineightpatientswithtype2diabetes.Self-
measured fasting glucose levels were re-
quired to be 150 mg/dl for inclusion
into the study. Patients with New York
Heart Association class III or IV heart fail-
ure,uncontrolledhypertension,impaired
kidneyfunction(creatinine3mg/dl),or
acute infection were excluded. The study
was approved by the local ethics commit-
teeandconductedfollowinggoodclinical
practices, and signed informed consent
wasobtainedfromalltheparticipants.Six
patients had histories of coronary artery
disease (two strokes, two myocardial in-
farctions, two coronary artery bypass
graftings, and two coronary artery revas-
cularizations). All the patients were
treated with oral antidiabetic drugs.
Investigations took place on two oc-
casions separated by 7  3 days. Patients
were admitted for a 1-day stay at the Me-
tabolism and Vascular Research Unit. Af-
ter an overnight fast, patients received a
standardized breakfast (634 kcal, 100 g
carbohydrates, 35 g fat, and 13.6 g pro-
tein). Treatment started 30 min after the
end of the test meal. Patients were ran-
domized to either the insulin infusion
protocol as used in the Munich registry
(10) or a continuous GLP-1 infusion (Cli-
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of 1.2 pmol   kg
1   min
1 for 8 h. Both
groups received a concomitant glucose
(10%) infusion at a rate of 30 ml/h; blood
glucose measurements were performed
every 30 min or at symptoms of hypogly-
cemia.Theprimaryoutcomewasthetime
taken to reach a plasma glucose level be-
low 115 mg/dl, and the secondary out-
come parameters were plasma glucose
after 2 and 4 h, as well as maximum gly-
cemia and the number of hypoglycemic
episodes. Differences of study variables
weretestedbyusingANOVAforrepeated
measurements or paired Student’s t test.
RESULTS— We investigated eight pa-
tients (ﬁve male) with a mean age of
58.2  2.3 years, a BMI of 24.4  1.0
kg/m
2, and an A1C of 7.3  0.7%. Glu-
cose levels at the start of infusion therapy
were comparable on both days of investi-
gation (insulin 252  42 mg/dl, GLP-1
244  24 mg/dl).
The primary end point (the time to
reach plasma glucose below 115 mg/dl)
was signiﬁcantly shorter during GLP-1
administration (252  51 vs. 321  43
min, P  0.01) (Fig. 1). Maximum glyce-
mia (312  51 vs. 254  48 mg/dl, P 
0.01), glycemia after 2 h (271  51 vs.
168  48 mg/dl, P  0.012), and glyce-
mia after 4 h (155  51 vs. 116  27
mg/dl,P0.02)weresigniﬁcantlyhigher
during insulin administration in compar-
ison with GLP-1. Glycemia after8h—a t
the end of the intervention — was com-
parable between both regimens (insulin
110  24 mg/dl, GLP-1 103  22 mg/dl,
P  NS). Serum insulin levels were gen-
erallylowerduringGLP-1treatment(data
not shown). One symptomatic hypogly-
cemia occurred during insulin infusion
(48 mg/dl), whereas no hypoglycemia
was noted in the GLP-1 regimen. Nausea
wasobservedinonepatientduringGLP-1
infusion.
CONCLUSIONS— Our study com-
pared for the ﬁrst time an established in-
sulin infusion regimen with a GLP-1–
infusion regimen in nonfasted type 2
diabetic patients regarding the efﬁcacy to
normalize hyperglycemia.
We clearly showed that glucose tar-
gets could be achieved faster with the
GLP-1–based regimen in comparison
with the insulin regimen, and that maxi-
mal glycemic excursions were markedly
reduced. Beside the advantage in time
course of lowering hyperglycemia, there
is no need for frequent blood glucose
measurements and subsequent dose ad-
aptations as is required when using intra-
venous insulin. Our pilot study, thus,
indicates that GLP-1–based regimens
should be further tested in acute clinical
settings (e.g., in hyperglycemic patients
with acute myocardial infarction or un-
dergoing vascular surgery where hyper-
glycemia was shown to predict a worse
outcome) (1–6).
Until now, blood glucose lowering in
this setting was performed by variable in-
sulin infusion protocols that may cause
hypoglycemia. High rates of hypoglyce-
mia, in turn, were discussed as a possible
explanation for the worse outcome of the
intensive control arm (6.8 vs. 0.5% in the
conventionalarm)intheNICEtrial(8).In
addition, Kosiborod et al. (7) recently
showed that the relation between mean
in-hospital blood glucose and mortality
rate is J-shaped, indicating that a low
mean blood glucose or recurring hypo-
glycemic episodes are associated with a
worse outcome. In that regard, a GLP-1
regimen has the clear advantage not to
cause hypoglycemia.
Preserved capacity of insulin secre-
tion is important for adequate GLP-1 ac-
tion, thus type 1 diabetic subjects as well
as insulin-treated type 2 diabetic patients
might not respond sufﬁciently to GLP-1
infusion. Since postprandial hyperglyce-
mia is the main target for GLP-1 due to
additional inhibitory effects on gastroin-
testinal motility, our study might overes-
timate the therapeutic potential (11).
Previous studies, however, could also
demonstrate a clear beneﬁcial effect of
GLP-1 on fasting glycemia (12).
In summary, the results of our pilot
trial indicate that for hyperglycemic clin-
ically stable type 2 diabetic patients, a
GLP-1–based infusion regimen is supe-
rior to an insulin-based regimen in effec-
tiveness and practicability for reaching
normoglycemia. We suggest that GLP-1–
based treatment strategies should be fur-
ther tested in hyperglycemic patients
under conditions of acute illness with re-
gardtoeffectivenessaswellasclinicalend
points.
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